{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:10:42Z","timestamp":1789679442104,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Evaluate patterns of stringent disease control with 2 years of guselkumab across key disease-identified domains and patient-reported outcomes (PROs) in subgroups of patients with psoriatic arthritis (PsA) defined by baseline characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This post hoc analysis of DISCOVER-2 (Clinicaltrials.gov NCT03158285) evaluated biologic-na\u00efve PsA patients (\u2265\u20095 swollen\/\u2009\u2265\u20095 tender joints, C-reactive protein [CRP]\u2009\u2265\u20090.6 mg\/dL) randomized to guselkumab every\u00a04\u00a0weeks (Q4W); guselkumab at Weeks\u00a00\u00a0and 4, then\u00a0Q8W; or placebo with crossover to guselkumab Q4W at Week\u00a024. Achievement of American College of Rheumatology 50\/70% improvement (ACR50\/70), Investigator\u2019s Global Assessment (IGA) 0, dactylitis\/enthesitis resolution, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue response (\u2265\u20094-point improvement), HAQ-Disability Index (HAQ-DI) response (\u2265\u20090.35-point improvement), PsA Disease Activity Score (PASDAS) low disease activity (LDA), and minimal disease activity (MDA) was assessed at Weeks 24, 52, and 100 in subgroups defined by sex and baseline medication use, body mass index, PsA duration, swollen\/tender joints, CRP, and psoriasis severity\/extent. Patients with missing categorical response data were considered nonresponders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>442\/493 (90%) guselkumab-randomized patients completed treatment through Week 100. Significant multi-domain efficacy of guselkumab versus placebo was shown across adequately sized patient subgroups. A pattern of continuous improvement was observed across key PsA domains and PROs within patient subgroups: 65%\u201385% of guselkumab-randomized patients had enthesitis\/dactylitis resolution, 50%\u201370% achieved complete skin clearance, 60%\u201380% reported meaningful improvements in function\/fatigue, 40%\u201365% achieved PASDAS LDA, and 35%\u201350% achieved MDA at Week\u00a0100.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with active PsA receiving guselkumab demonstrated durable achievement of stringent endpoints associated with disease control across key PsA domains and PROs, regardless of baseline characteristics.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Among biologic-na\u00efve patients with highly active psoriatic arthritis (PsA), efficacy of guselkumab across stringent disease endpoints and patient-reported outcomes (PROs) at Week 24 was consistent regardless of baseline demographics and disease characteristics.<\/jats:italic><jats:italic>\u2022 Within guselkumab-randomized PsA patient subgroups, major improvements in joint disease activity, complete skin clearance, dactylitis\/enthesitis resolution, clinically meaningful improvements in PROs, and achievement of low overall disease activity were maintained through Week 100.<\/jats:italic><jats:italic>\u2022 Durable stringent endpoint achievement indicating disease control was observed with guselkumab, regardless of baseline patient or disease characteristics.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s10067-024-06991-8","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:32:14Z","timestamp":1717731134000},"page":"2551-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-7124","authenticated-orcid":false,"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-7171","authenticated-orcid":false,"given":"John","family":"Tesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-5292","authenticated-orcid":false,"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"6991_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053","journal-title":"Ann Rheum Dis"},{"key":"6991_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheum 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheum"},{"key":"6991_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2019) Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheum 71:5\u201332. https:\/\/doi.org\/10.1002\/art.40726","journal-title":"Arthritis Rheum"},{"key":"6991_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3899\/jrheum.181272","volume":"47","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Eusebio M, Avila-Ribeiro P et al (2020) Real-world longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the Rheumatic Diseases Portuguese Register. J Rheumatol 47:690\u2013700. https:\/\/doi.org\/10.3899\/jrheum.181272","journal-title":"J Rheumatol"},{"key":"6991_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/rheumatology\/kead284","volume":"63","author":"L Linde","year":"2023","unstructured":"Linde L, Ornbjerg LM, Georgiadis S et al (2023) Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries. Rheumatology (Oxford) 63:751\u2013764. https:\/\/doi.org\/10.1093\/rheumatology\/kead284","journal-title":"Rheumatology (Oxford)"},{"key":"6991_CR6","doi-asserted-by":"publisher","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A et al (2021) Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open 7:e001519. https:\/\/doi.org\/10.1136\/rmdopen-2020-001519","journal-title":"RMD Open"},{"key":"6991_CR7","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/rheumatology\/kead089","volume":"62","author":"AWR Van Kuijk","year":"2023","unstructured":"Van Kuijk AWR, Nurmohamed MT, Siebert S et al (2023) Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology (Oxford) 62:3382\u20133390. https:\/\/doi.org\/10.1093\/rheumatology\/kead089","journal-title":"Rheumatology (Oxford)"},{"key":"6991_CR8","unstructured":"Eder L, Coates LC, Nash P et al (2022) Impact of patient characteristics, including sex, on the efficacy of upadacitinib compared with adalimumab in patients with psoriatic arthritis [abstract]. Arthritis Rheumatol 74. https:\/\/acrabstracts.org\/abstract\/impact-of-patient-characteristics-including-sex-on-the-efficacy-of-upadacitinib-compared-with-adalimumab-in-patients-with-psoriatic-arthritis\/"},{"key":"6991_CR9","first-page":"19","volume":"38","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Conti F, Selmi C et al (2020) Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol 38:19\u201326","journal-title":"Clin Exp Rheumatol"},{"key":"6991_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH et al (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1115\u20131125. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8","journal-title":"Lancet"},{"key":"6991_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB et al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1126\u20131136. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4","journal-title":"Lancet"},{"key":"6991_CR12","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH et al (2021) Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open 7:e001457. https:\/\/doi.org\/10.1136\/rmdopen-2020-001457","journal-title":"RMD Open"},{"key":"6991_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB et al (2022) Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol 74:475\u2013485. https:\/\/doi.org\/10.1002\/art.42010","journal-title":"Arthritis Rheumatol"},{"key":"6991_CR14","doi-asserted-by":"publisher","first-page":"e002195","DOI":"10.1136\/rmdopen-2022-002195","volume":"8","author":"CT Ritchlin","year":"2022","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH et al (2022) Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open 8:e002195. https:\/\/doi.org\/10.1136\/rmdopen-2022-002195","journal-title":"RMD Open"},{"key":"6991_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59:686\u2013691. https:\/\/doi.org\/10.1002\/art.23568","journal-title":"Arthritis Rheum"},{"key":"6991_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236. https:\/\/doi.org\/10.1002\/art.20967","journal-title":"Arthritis Rheum"},{"key":"6991_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica 157:238\u2013244. https:\/\/doi.org\/10.1159\/000250839","journal-title":"Dermatologica"},{"key":"6991_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RGB Langley","year":"2015","unstructured":"Langley RGB, Feldman SR, Nyirady J et al (2015) The 5-point Investigator\u2019s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 26:23\u201331. https:\/\/doi.org\/10.3109\/09546634.2013.865009","journal-title":"J Dermatolog Treat"},{"key":"6991_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:20. https:\/\/doi.org\/10.1186\/1477-7525-1-20","journal-title":"Health Qual Life Outcomes"},{"key":"6991_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C et al (2007) Functional Assessment of Chronic Illness Therapy-Fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 66:936\u2013939. https:\/\/doi.org\/10.1136\/ard.2006.065763","journal-title":"Ann Rheum Dis"},{"key":"6991_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"6991_CR22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Gladman DD, Poddubnyy D et al (2023) Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther 10:1637\u20131653. https:\/\/doi.org\/10.1007\/s40744-023-00592-8","journal-title":"Rheumatol Ther"},{"key":"6991_CR23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201341","journal-title":"Ann Rheum Dis"},{"key":"6991_CR24","doi-asserted-by":"publisher","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","volume":"64","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Antoni CE, Gladman DD et al (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64:ii49-54. https:\/\/doi.org\/10.1136\/ard.2004.034165","journal-title":"Ann Rheum Dis"},{"key":"6991_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B et al (2011) Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38:2461\u20132465. https:\/\/doi.org\/10.3899\/jrheum.110546","journal-title":"J Rheumatol"},{"key":"6991_CR26","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M et al (2005) Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811\u2013819","journal-title":"J Rheumatol"},{"key":"6991_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB et al (2021) Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol 73:604\u2013616. https:\/\/doi.org\/10.1002\/art.41553","journal-title":"Arthritis Rheumatol"},{"key":"6991_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M et al (2016) Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 75:77-82.e77. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026","journal-title":"J Am Acad Dermatol"},{"key":"6991_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE et al (2015) Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat 26:235\u2013239. https:\/\/doi.org\/10.3109\/09546634.2014.943687","journal-title":"J Dermatolog Treat"},{"key":"6991_CR30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000113150","volume":"216","author":"DA Revicki","year":"2008","unstructured":"Revicki DA, Willian MK, Menter A et al (2008) Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 216:260\u2013270. https:\/\/doi.org\/10.1159\/000113150","journal-title":"Dermatology"},{"key":"6991_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE et al (2021) Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol 185:1146\u20131159. https:\/\/doi.org\/10.1111\/bjd.20568","journal-title":"Br J Dermatol"},{"key":"6991_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/acr2.11537","volume":"5","author":"D McGonagle","year":"2023","unstructured":"McGonagle D, McInnes IB, Deodhar A et al (2023) Guselkumab, a selective interleukin-23 p19 subunit inhibitor, resolves dactylitis in patients with active psoriatic arthritis: pooled results through week 52 from two phase 3 studies. ACR Open Rheumatol 5:227\u2013240. https:\/\/doi.org\/10.1002\/acr2.11537","journal-title":"ACR Open Rheumatol"},{"key":"6991_CR33","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","volume":"60","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, McInnes IB, Deodhar A et al (2021) Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford) 60:5337\u20135350. https:\/\/doi.org\/10.1093\/rheumatology\/keab285","journal-title":"Rheumatology (Oxford)"},{"key":"6991_CR34","doi-asserted-by":"publisher","first-page":"e003977","DOI":"10.1136\/rmdopen-2023-003977","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Gossec L, Zimmermann M et al (2024) Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open 10:e003977. https:\/\/doi.org\/10.1136\/rmdopen-2023-003977","journal-title":"RMD Open"},{"key":"6991_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease P et al (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673\u2013680. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210242","journal-title":"Ann Rheum Dis"},{"key":"6991_CR36","volume-title":"Comparison of on-label treatment persistence in real-world patients with psoriatic arthritis receiving guselkumab versus subcutaneous TNF inhibitors","author":"J Walsh","year":"2023","unstructured":"Walsh J, Lin I, Zhao R et al (2023) Comparison of on-label treatment persistence in real-world patients with psoriatic arthritis receiving guselkumab versus subcutaneous TNF inhibitors. Congress of Clincal Rheumatology-West, San Diego, CA"},{"key":"6991_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B et al (2022) Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol 158:1131\u20131141. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2909","journal-title":"JAMA Dermatol"},{"key":"6991_CR38","doi-asserted-by":"publisher","first-page":"e001679","DOI":"10.1136\/rmdopen-2021-001679","volume":"7","author":"K Sweet","year":"2021","unstructured":"Sweet K, Song Q, Loza MJ et al (2021) Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open 7:e001679. https:\/\/doi.org\/10.1136\/rmdopen-2021-001679","journal-title":"RMD Open"},{"key":"6991_CR39","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/annrheumdis-2023-eular.604","volume":"82","author":"S Siebert","year":"2023","unstructured":"Siebert S, Schett G, Raychaudhuri SP et al (2023) AB1085 Changes in serum cytokines and collagen proteins correlate with durability of guselkumab efficacy and continued disease improvement through 2 years in patients with active psoriatic arthritis. Ann Rheum Dis 82:1763\u20131764. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.604","journal-title":"Ann Rheum Dis"},{"key":"6991_CR40","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2023-eular.826","volume":"82","author":"D McGonagle","year":"2023","unstructured":"McGonagle D, Atreya R, Abreu M et al (2023) POS1531 Guselkumab, an IL-23p19 subunit\u2013specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Ann Rheum Dis 82:1128\u20131129. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.826","journal-title":"Ann Rheum Dis"},{"key":"6991_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3899\/jrheum.220928","volume":"50","author":"P Rahman","year":"2023","unstructured":"Rahman P, Boehncke WH, Mease PJ et al (2023) Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol 50:769\u2013780. https:\/\/doi.org\/10.3899\/jrheum.220928","journal-title":"J Rheumatol"},{"key":"6991_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2023","unstructured":"Strober B, Coates LC, Lebwohl MG et al (2023) Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf 47:39\u201357. https:\/\/doi.org\/10.1007\/s40264-023-01361-w","journal-title":"Drug Saf"},{"key":"6991_CR43","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s13555-023-01012-z","volume":"13","author":"AM Orbai","year":"2023","unstructured":"Orbai AM, Chakravarty SD, You Y et al (2023) Efficacy of guselkumab in treating nails, scalp, hands, and feet in patients with psoriasis and self-reported psoriatic arthritis. Dermatol Ther (Heidelb) 13:2859\u20132868. https:\/\/doi.org\/10.1007\/s13555-023-01012-z","journal-title":"Dermatol Ther (Heidelb)"},{"key":"6991_CR44","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Ogdie A, Tesser J et al (2023) Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Rheumatol Ther 10:1479\u20131501. https:\/\/doi.org\/10.1007\/s40744-023-00582-w","journal-title":"Rheumatol Ther"},{"key":"6991_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-022-00518-w","volume":"10","author":"S Siebert","year":"2023","unstructured":"Siebert S, Behrens F, Lubrano E et al (2023) PsABIOnd study and eDaily substudy design: long-term effectiveness and safety of guselkumab and IL-17 inhibitors in routine clinical practice in patients with psoriatic arthritis. Rheumatol Ther 10:489\u2013505. https:\/\/doi.org\/10.1007\/s40744-022-00518-w","journal-title":"Rheumatol Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06991-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:14:27Z","timestamp":1721823267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06991-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["6991"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06991-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>CTR:<\/b> Received grant\/research support from AbbVie, Amgen, UCB and consulting fees from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB. <b>PJM:<\/b> Received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, and\u00a0Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>WHB:<\/b> Received honoraria as a speaker and advisor from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and UCB. <b>JT:<\/b> Has served on advisory boards\/as a consultant for: AbbVie, Amgen, AstraZeneca, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Samumed\/ Biosplice, Sanofi-Genzyme, UCB; served on speaker bureaus for: AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb (through 2021), Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Sanofi\/Genzyme; received research grants and support from: AbbVie, Alpine, Amgen, Anthrosi, Bendcare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, CSL Behring, DRL, Eli Lilly, Emerald, Exagen, Genentech, Gilead, Global Health Living Foundation, Horizon, Janssen, Kolon TissueGene, Mitsubishi, Organogenesis, Pfizer, Samumed\/Biosplice, Selecta, Setpoint, Sun, Takeda, and Vorso. <b>SDC:<\/b> Employee of Janssen Scientific Affairs, LLC, and owns stock in Johnson & Johnson. <b>ER:<\/b> Employee of JSS Medical Research; paid consultant of Janssen. <b>MS:<\/b> Employee of Janssen Research & Development, LLC, and owns stock in Johnson & Johnson.\u00a0<b>ES:\u00a0<\/b>Received consulting fees and research grants from Janssen <b>JFM:<\/b> Received consulting fees and investigator honoraria from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo, Novartis, Pfizer, Regeneron, Sanofi, Sun, and UCB. Current affiliation: Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA. <b>IBM:<\/b> Received consulting fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant\/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Roche, and UCB; is a shareholder for Causeway, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee. <b>AD:<\/b> Received consulting fees for participation in advisory boards from Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; research grant funding from Eli Lilly, Novartis, Pfizer, and UCB; and speaker fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Janssen Research & Development, LLC had a role in the study design and in the collection, analysis, and interpretation of the data, the writing of the manuscript, and the decision to submit the manuscript for publication. Publication of this article was contingent upon approval by Janssen Research & Development, LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the study sponsor"}}]}}